142 related articles for article (PubMed ID: 22332705)
1. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM; Gandra SR; Fox KM; Wilson KL
J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
[TBL] [Abstract][Full Text] [Related]
2. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study.
Ogale S; Hitraya E; Henk HJ
BMC Musculoskelet Disord; 2011 Sep; 12():204. PubMed ID: 21929807
[TBL] [Abstract][Full Text] [Related]
3. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH
J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
[TBL] [Abstract][Full Text] [Related]
4. CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis.
Krintel SB; Essioux L; Wool A; Johansen JS; Schreiber E; Zekharya T; Akiva P; Ostergaard M; Hetland ML
PLoS One; 2012; 7(6):e38539. PubMed ID: 22685579
[TBL] [Abstract][Full Text] [Related]
5. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
Curtis JR; Chastek B; Becker L; Quach C; Harrison DJ; Yun H; Joseph GJ; Collier DH
J Manag Care Spec Pharm; 2015 Apr; 21(4):318-29. PubMed ID: 25803765
[TBL] [Abstract][Full Text] [Related]
6. Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis.
Grabner M; Boytsov NN; Huang Q; Zhang X; Yan T; Curtis JR
Arthritis Res Ther; 2017 May; 19(1):92. PubMed ID: 28506320
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid arthritis: travelling biological era a Romanian X-ray population.
Mogosan C; Stoica V; Mihai C; Macovei L; Ancuta I; Ciofu C; Stefanescu F; Bojinca M; Martin A; Milicescu M; Crisan V; Banciu M; Suteanu S
J Med Life; 2009; 2(4):414-25. PubMed ID: 20108756
[TBL] [Abstract][Full Text] [Related]
8. Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis.
Sangiorgi D; Benucci M; Nappi C; Perrone V; Buda S; Degli Esposti L
Biologics; 2015; 9():119-27. PubMed ID: 26604680
[TBL] [Abstract][Full Text] [Related]
9. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases.
Ducourau E; Mulleman D; Paintaud G; Miow Lin DC; Lauféron F; Ternant D; Watier H; Goupille P
Arthritis Res Ther; 2011 Jun; 13(3):R105. PubMed ID: 21708018
[TBL] [Abstract][Full Text] [Related]
10. Age, Sex, Metabolic and Pharmacologic Factors May Predict Nonresponse Status to Rheumatoid Arthritis Therapies.
Bordean L; Chis M; Cimpean AM; Barb AC; Cosma AA; Fenesan MP; Cotoi OS; Nicolescu L; Nicolescu CM; Avram C
In Vivo; 2023; 37(5):2387-2401. PubMed ID: 37652478
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study.
D'Souza A; Meissner BL; Tang B; McKenzie RS; Piech CT
Am Health Drug Benefits; 2010 Jul; 3(4):266-73. PubMed ID: 25126319
[TBL] [Abstract][Full Text] [Related]
12. Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy.
Degli Esposti L; Favalli EG; Sangiorgi D; Di Turi R; Farina G; Gambera M; Ravasio R
Clinicoecon Outcomes Res; 2017; 9():9-17. PubMed ID: 28053549
[TBL] [Abstract][Full Text] [Related]
13. Role of Tumor Necrosis Factor-α Inhibitors in the Treatment and Occurrence of Acne: A Systematic Review.
Sandoval AGW; Vaughn LT; Huang JT; Barbieri JS
JAMA Dermatol; 2023 May; 159(5):504-509. PubMed ID: 36930143
[TBL] [Abstract][Full Text] [Related]
14. Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Naïve Patients with Rheumatoid Arthritis.
Spivey CA; Winthrop KL; Griffith J; Kaplan CM; Qiao Y; Postlethwaite AE; Wang J
Rheumatol Ther; 2020 Mar; 7(1):133-147. PubMed ID: 31741182
[TBL] [Abstract][Full Text] [Related]
15. Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009-2014.
Tłustochowicz M; Śliwczyński AM; Brzozowska M; Teter Z; Marczak M
Arch Med Sci; 2018 Apr; 14(3):569-571. PubMed ID: 29765444
[TBL] [Abstract][Full Text] [Related]
16. Infliximab dosing patterns in a sample of patients with Crohn's disease: results from a medical chart review.
Tkacz J; Lofland JH; Vanderpoel J; Ruetsch C
Am Health Drug Benefits; 2014 Apr; 7(2):87-93. PubMed ID: 24991393
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life of patients with rheumatoid arthritis on tocilizumab, adalimumab, and etanercept in Saudi Arabia: a single-center cross-sectional study.
Alotaibi AM; Albahdal AS; Abanmy N; Alwhaibi M; Asiri Y; AlRuthia Y
Front Pharmacol; 2023; 14():1299630. PubMed ID: 38161694
[No Abstract] [Full Text] [Related]
18. Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study.
Wang N; Guo Y; Yang L; Fu W; Xu Y; Hou L; Zhao S; Zhang N
Neural Regen Res; 2012 Apr; 7(11):862-6. PubMed ID: 25737715
[TBL] [Abstract][Full Text] [Related]
19. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
